NASDAQ:CELU Celularity (CELU) Stock Price, News & Analysis $2.94 +0.02 (+0.68%) (As of 11/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Celularity Stock (NASDAQ:CELU) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Celularity alerts:Sign Up Key Stats Today's Range$2.77▼$3.0650-Day Range$1.38▼$3.8352-Week Range$1.30▼$7.97Volume120,755 shsAverage Volume3.18 million shsMarket Capitalization$64.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCelularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.Read More… [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Celularity Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks11th Percentile Overall ScoreCELU MarketRank™: Celularity scored higher than 11% of companies evaluated by MarketBeat, and ranked 931st out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Celularity. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioCelularity has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Celularity's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.92% of the float of Celularity has been sold short.Short Interest Ratio / Days to CoverCelularity has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Celularity has recently increased by 9.29%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCelularity does not currently pay a dividend.Dividend GrowthCelularity does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.92% of the float of Celularity has been sold short.Short Interest Ratio / Days to CoverCelularity has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Celularity has recently increased by 9.29%, indicating that investor sentiment is decreasing significantly. News and Social Media3.2 / 5News Sentiment0.77 News SentimentCelularity has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Celularity this week, compared to 1 article on an average week.Search Interest4 people have searched for CELU on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Celularity to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Celularity insiders have not sold or bought any company stock.Percentage Held by Insiders20.70% of the stock of Celularity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 19.02% of the stock of Celularity is held by institutions.Read more about Celularity's insider trading history. Receive CELU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celularity and its competitors with MarketBeat's FREE daily newsletter. Email Address CELU Stock News HeadlinesCelularity’s Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia PacificNovember 20 at 11:22 AM | markets.businessinsider.comCelularity's Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia PacificNovember 20 at 8:30 AM | globenewswire.com“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…November 21, 2024 | Colonial Metals (Ad)Celularity Inc. (NASDAQ:CELU) Sees Large Increase in Short InterestNovember 19 at 1:29 AM | americanbankingnews.comCelularity Inc. Announces Resolution of Nasdaq Listing Compliance MatterNovember 18 at 8:30 AM | globenewswire.comCelularity (NASDAQ:CELU) Stock Quotes, Forecast and News SummaryNovember 8, 2024 | benzinga.comCelularity raises FY24 revenue view to $54M-$60M from $50M-$56MNovember 7, 2024 | markets.businessinsider.comCelularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 MillionNovember 7, 2024 | finance.yahoo.comSee More Headlines CELU Stock Analysis - Frequently Asked Questions How have CELU shares performed this year? Celularity's stock was trading at $2.4740 at the beginning of 2024. Since then, CELU stock has increased by 18.8% and is now trading at $2.94. View the best growth stocks for 2024 here. How were Celularity's earnings last quarter? Celularity Inc. (NASDAQ:CELU) issued its earnings results on Wednesday, October, 16th. The company reported ($1.03) EPS for the quarter. The business earned $14.68 million during the quarter. Celularity had a negative trailing twelve-month return on equity of 92.48% and a negative net margin of 264.30%. When did Celularity's stock split? Celularity's stock reverse split on the morning of Thursday, February 29th 2024. The 1-10 reverse split was announced on Thursday, February 29th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Celularity's major shareholders? Top institutional shareholders of Celularity include Geode Capital Management LLC (0.63%). Insiders that own company stock include Kok Thay Lim and Robert J Hariri. View institutional ownership trends. How do I buy shares of Celularity? Shares of CELU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Celularity own? Based on aggregate information from My MarketBeat watchlists, some other companies that Celularity investors own include NVIDIA (NVDA), Meta Platforms (META), Lovesac (LOVE), MannKind (MNKD), PayPal (PYPL), Tesla (TSLA) and Advanced Micro Devices (AMD). Company Calendar Last Earnings10/16/2024Today11/21/2024Fiscal Year End12/31/2024Next Earnings (Estimated)1/07/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CELU CUSIPN/A CIK1752828 Webwww.celularity.com Phone908-768-2170FaxN/AEmployees220Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-196,290,000.00 Net Margins-264.30% Pretax Margin-264.28% Return on Equity-92.48% Return on Assets-20.76% Debt Debt-to-Equity RatioN/A Current Ratio0.26 Quick Ratio0.22 Sales & Book Value Annual Sales$42.69 million Price / Sales1.51 Cash Flow$8.91 per share Price / Cash Flow0.33 Book Value$2.11 per share Price / Book1.39Miscellaneous Outstanding Shares21,985,000Free Float17,434,000Market Cap$64.64 million OptionableOptionable Beta0.51 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:CELU) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celularity Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celularity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.